Resolution of Retinal Detachment

Article

Retinal detachment found to resolve in retinoblastoma patients following intraarterial chemotherapy

"Retinal detachment will resolve following intraarterial chemotherapy (IAC), and its rate and completeness of resolution depends on the extent of the retinal detachment," according to Dr Carol Shields (Ocular Oncology Service, Wills Eye Institute, Philadelphia, Pennsylvania, USA) when discussing the results of a recent study on the effect of IAC on retinoblastoma induced retinal detachments.1

In the retrospective, non-comparative, interventional case series, Dr Shields and colleagues examined 15 patients that were all undergoing IAC treatment for retinoblastoma. Data was collected retrospectively on all patients that met the inclusion criteria until the final followup visit.

Results and discussion

Out of the 15 patients examined, 7 had a total retinal detachment and 8 had a partial retinal detachment. "We found that the retinal detachment resolved completely if it was partial at presentation and often completely in cases of total retinal detachment," said Dr Shields. "Following chemotherapy, the retinoblastoma resolves fast, within 1–2 months, and the retinal detachment lags with slower resolution over 3–4 months."

In the group of patients with total retinal detachment, 3 patients achieved complete resolution of fluid and 4 patients achieved partial resolution. For the group of patients presenting with partial detachment there was 100% resolution achieved.

Previously, if a patient had total retinal detachment it was common to perform enucleation as it was presumed that there would be no visual potential noted Dr Shields. "Now, with IAC, we enucleate less often as we know that retinal detachment will probably completely resolve following treatment," she said.

"We are constantly looking at our data and results on IAC for retinoblastoma," added Dr Shields. "It would be nice to measure resolution per exact degree of retinal elevation so that we could better predict the rate of resolution and completeness of resolution."

Special contributor

Dr Carol Shields is an ocular oncologist at the Ocular Oncology Service, Wills Eye Institute, Philadelphia, Pennsylvania, USA. She may be reached by Email: carol.shields@shieldsoncology.com

Dr Shields has indicated she has no financial interests in the subject matter.

Reference

1. C. Shields et al., Retina, 2012;32(4):799–804.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Sunita Radhakrishnan, MD, an associate at the Glaucoma Center of San Francisco, speaks at the annual Glaucoma 360 meeting about electrical neurostimulation.
Related Content
© 2025 MJH Life Sciences

All rights reserved.